Patent US5433870A successfully refreshed from Google Patents.
Patent US5789000A successfully refreshed from Google Patents.
US5789000A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
Assignee: BioNumerik Pharmaceuticals Inc
•
Filing: 1994-11-14
•
Granted: 1998-08-04
•
Expires: 2014-11-14
Abstract
Abstract This invention describes a novel formulation containing both cis-diammine dichloro platinum and a water soluble disulfide, 2,2'-dithio-bis-ethane sulfonate in the same solution, wherein the presence of the disulfide and the parenteral administration of the formulation reduces the risk of cisplatin induced nephrotoxicity when treating human patients with cancer.
Inventors
- 👤 Frederick H. Hausheer
- 👤 Kochat Haridas
- 👤 Dhanabalan Murali
- 👤 Dasharatha Gauravaram Reddy
- 👤 Peddaiahgari Seetharamulu
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 20:14
CPC Classifications
A; A61; A61K; A61K33/00; A61K33/24; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61K31/185; A61K31/21; A61K31/255; A61K31/28; A61K31/40; A61K33/243; A61K45/00; A61K45/06; A61P; A61P31/00; A61P35/00; A61P39/00; A61P39/02; A61P43/00
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
124 words
An injectable, sterile, stable aqueous solution consisting of cis-diammine dichloro platinum, 2,2'-dithio-bis-ethane sulfonate, sodium chloride and hydrochloric acid in a unit dosage form in a sealed container, wherein said solution is suitable for intravenous administration to human patients with cancer by the injection thereof from said container, wherein said concentration of cis-diammine dichloro platinum is between about 0.1 mg/ml and about 1.0 mg/ml, wherein said concentration of 2,2'-dithio-bis-ethane sulfonate is between about 5 mg per ml and about 100 mg per ml by weight of water, wherein said concentration of sodium chloride is between about 0.9% and about 3.0% by weight of water, and wherein said hydrochloric acid is in an amount sufficient to maintain the pH in the range of 2.0 to 6.0.
Claim 2
Dependent Claim
124 words
An injectable, sterile, stable aqueous solution consisting of cis-diammine dichloro platinum, 2,2'-dithio-bis-ethane sulfonate, sodium chloride and hydrochloric acid in a unit dosage form in a sealed container, wherein said solution is suitable for intravenous administration to human patients with cancer by the injection thereof from said container, wherein said concentration of cis-diammine dichloro platinum is between about 0.1 mg/ml and about 1.0 mg/ml, wherein said concentration of 2,2'-dithio-bis-ethane sulfonate is between about 5 mg per ml and about 100 mg per ml by weight of water, wherein said concentration of sodium chloride is between about 0.9% and about 3.0% by weight of water, and wherein said hydrochloric acid is in an amount sufficient to maintain the pH in the range of 2.0 to 6.0.
Claim 3
Dependent Claim
23 words
The injectable solution of claim 1 further consisting of mannitol in a concentration between about 1.0% and about 1.5% by weight of water.
Claim 4
Dependent Claim
41 words
The injectable solution of claim 2 wherein said solution is administered to human patients with cancer in combination with another anticancer agent or agents selected from the group consisting of 5-FU (5-Fluorouracil), bleomycin, VP-16 (etoposide), cyclophosphamide, ifosphamide, leucovorin, methotrexate, and vinblastine.
References Cited (Backward Citations)
EP0538858A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-08-03 | 2002-02-02 | 2002-08-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-08-03 | 2006-02-02 | 2006-08-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-08-03 | 2010-02-02 | 2010-08-04 | $7700.00 | Window Closed / Lapsed |